Previous close | 194.50 |
Open | 194.10 |
Bid | 197.90 x N/A |
Ask | 200.80 x N/A |
Day's range | 194.10 - 194.10 |
52-week range | 128.00 - 232.00 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Headwaters Capital Management, an investment management company, released its first-quarter 2024 investor letter. A copy of the investor letter can be downloaded here. The fund increased by +10.6% (+10.4% net) in the first quarter compared to a +8.6% return for the Russell Mid Cap Index. During Q1, large caps, led by the S&P 500 with […]
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe